NSCLC是脑转移的最常见原因；在诊断时，脑转移存在于患有转移性50％NTRK+NSCLC和患有转移性20-40％ROS1+NSCLC。

NSCLC is the most common cause of brain metastases; At diagnosis, BMS were present in patients with 50% metastatic NTRK+NSCLC and 20-40% metastatic ROS1+NSCLC.

恩曲替尼

　　在此医疗情况下，具有口服活性的小分子TKI恩曲替尼（TRKA/B/C、ROS1和ALK的选择性抑制剂）被设计为具有全身活性并能穿过血脑屏障，恩曲替尼虽然好，但也会耐药，恩曲替尼一旦耐药，也就没有治疗效果了，不过患者也不需要担心无药可用。

　　恩曲替尼耐药后可以用瑞博替尼，积极配合医生治疗，选择最适合自身的治疗方式，延长生命。

Rebotinib can be used after the drug resistance of emtraitinib, actively cooperate with doctors for treatment, choose the most suitable treatment for their own, and prolong their lives.